As per the latest report by IMARC Group, titled “Acne Drugs Market Report by Acne Type (Comedonal, Inflammatory, Cystic, Postsurgical/Wound), Drug Class (Retinoids, Antibiotics, Hormonal Agents, Combination Drugs, and Others), Drug Type (OTC Drugs, Prescription Drugs), Route of Administration (Topical, Oral, Injectable), and Region 2025-2033,” the global acne drugs market reached a value of USD 7.2 Billion in 2024. Acne is a dermatological condition that occurs when the hair follicles in the skin get clogged by sebum, dead skin cells and harmful bacteria. Although it is most common among teenagers, it can affect people of all ages. Factors like emotional stress, hot and humid climate and hormonal fluctuations during puberty can cause the onset of acne by enlarging oil glands under the skin. Acne drugs are used for treating bacterial infections or reduce oil production in the skin, which helps lower the occurrence of acne. These drugs include lifestyle remedies, topical and oral medicines, and medical procedures.
Global Acne Drugs Market Trends:
Acne is one of the most prevalent skin diseases globally and is estimated to affect 9.4% of the population worldwide. Along with this, the increasing prevalence of skin-related diseases due to genetic factors or heavy cosmetics has led to a significant rise in the demand for acne drugs across the globe. Moreover, dermatologists and researchers are developing safer and more advanced treatment drugs with a better understanding of acne pathology. For instance, Paratek and Allergen developed Sarecycline, an oral tetracycline-class drug, for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-modular moderate to severe acne vulgaris. Some of the other medications prescribed by dermatologists include topical retinoids, topical antibiotics, azelaic acid and antibiotic tablets, which are commonly used to treat moderate to severe acne. Looking forward, the market value is projected to reach USD 11.2 Billion by 2033, expanding at a CAGR of 4.9% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Acne Type, Drug Class, Drug Type, Route of Administration, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Allergan Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, Cipher Pharmaceuticals Inc., Galderma Holding SA, Johnson & Johnson, Pfizer Inc., Reckitt Benckiser Group Plc, Skinvisible Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800